Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Oncology›Condition·Updated Jun 21, 2026·v1

Cervical Cancer Recurrent and Metastatic Disease

Recurrent cervical cancer requires a multidisciplinary approach tailored to the site of failure. Localized central recurrences are managed with curative-intent pelvic exenteration, while metastatic disease is treated with a quadruplet regimen of platinum, paclitaxel, bevacizumab, and pembrolizumab (if PD-L1 positive).

High Evidence126 references·756 words·4 min read·v1
oncologycervical_cancerimmunotherapypembrolizumabpelvic_exenteration

Quick Reference

RxDrug of choicePembrolizumab (200mg q3w) + Bevacizumab (15mg/kg) + Platinum/Paclitaxel
AltAlternativesCadonilimab (bispecific PD-1/CTLA-4), Tisotumab vedotin (second-line)
⊘AvoidMinimally invasive surgery for radical hysterectomy (due to higher recurrence risk); Bevacizumab in patients with high risk of GI fistula.
DxTest of choicePET/CT for staging; Biopsy for confirmation
ScKey scorePD-L1 Combined Positive Score (CPS) ≥ 1
→When to referIsolated pelvic recurrence (for exenteration evaluation); Oligometastatic disease (for SBRT)
Management is bifurcated: ultra-radical surgery for isolated local relapse and quadruplet chemo-immunotherapy for metastatic disease.
Recurrent and metastatic cervical cancer requires a transition from curative-intent salvage to palliative systemic [[management]]. Approximately 30-50% of patients with locally advanced disease relapse, primarily within 3 years [3, 9, 46]. Modern management integrates ultra-radical surgery for local failure and triplet/quadruplet immunotherapy-based regimens for distant spread, with prognosis increasingly dictated by molecular biomarkers and PD-L1 expression [3, 86, 115].

Overview and Recommendations

Background

  • •Recurrence patterns in cervical cancer are categorized by anatomic distribution—local (vaginal vault/parametria), regional (pelvic/para-aortic nodes), and distant (visceral organs)—with approximately 30% to 50% of locally advanced cases relapsing after definitive therapy.
  • •The temporal peak for recurrence occurs within the first 36 months of follow-up, making intensive surveillance during this window critical for identifying patients eligible for curative salvage therapy.
  • •Surgical technique serves as a primary driver of local control; the landmark LACC trial demonstrated that minimally invasive radical results in significantly higher recurrence rates compared to open surgery (86.0% vs 96.5% 4.5-year DFS), leading to a global shift back to open surgical approaches.
  • •Nodal status and biological markers such as tumor-related leukocytosis (WBC > 9,000/μL) and persistent high-risk (HPV) (ctDNA) identify high-risk phenotypes prone to early systemic failure.
  • •Distant metastasis most frequently involves the lungs, followed by the liver and bone, with liver involvement serving as a particularly poor prognostic indicator for overall survival.

Evaluation

  • •Suspect recurrence in any patient with a history of cervical cancer presenting with new-onset pelvic pain, unexplained weight loss, vaginal bleeding, or persistent lower extremity edema.
  • •Perform a thorough physical examination including a speculum exam, bimanual pelvic exam, and palpation of supraclavicular and inguinal lymph nodes to identify accessible sites for biopsy.
  • •Order a PET/CT or chest/abdomen/pelvis CT with IV contrast as the initial imaging modality to differentiate between isolated local recurrence and widely disseminated metastatic disease.
  • •Obtain a tissue biopsy of the suspected recurrence whenever feasible; histological confirmation is mandatory before initiating toxic systemic therapy or proceeding to ultra-radical surgery.
  • •Assess PD-L1 expression using the Combined Positive Score (CPS) on the biopsy specimen; a CPS ≥ 1 is the requisite threshold for the addition of to first-line systemic therapy.
  • •Evaluate the neutrophil-to-lymphocyte ratio (NLR) and serum lactate dehydrogenase (LDH) as these markers provide independent prognostic value regarding progression-free survival.
  • •Screen for sarcopenia and nutritional deficits using CT-based muscle body composite measurements in patients being considered for pelvic exenteration, as these factors predict high postoperative morbidity.
  • •Utilize MRI for local staging in patients with suspected central pelvic recurrence to assess for bladder or rectal involvement and to determine the feasibility of an R0 (margin-negative) resection.

Management

  • •Initiate first-line systemic therapy for metastatic or non-resectable recurrent disease with a quadruplet regimen:
    (or ) + .
  • •Administer at 200 mg IV every 3 weeks or 400 mg IV every 6 weeks for patients with PD-L1 CPS ≥ 1; this addition reduces the risk of death by approximately 37-40%.
  • •Dose at 15 mg/kg IV every 3 weeks, but exercise caution in patients with prior pelvic radiation due to a 10-15% risk of gastrointestinal perforations or fistulas.
  • •Perform pelvic exenteration (en bloc resection of pelvic organs) for isolated central recurrences in previously irradiated fields where R0 resection is achievable; this offers a median overall survival of 38.7 months.
  • •Utilize (SBRT) for oligometastatic disease (limited number of lesions), typically delivering 39 Gy in 3 fractions to achieve durable local control.
  • •Consider laterally extended endopelvic resection (LEER) for recurrences involving the lateral pelvic wall, though this requires highly specialized surgical expertise to ensure clear margins.
  • •Apply high-dose-rate (HDR) interstitial for localized failures in patients who are not surgical candidates, using gel spacers to protect the bladder and rectum from radiation toxicity.
  • •Monitor for treatment-related toxicities, particularly immune-related adverse events from and hypertension or proteinuria from .
  • •Refer patients with brain or cutaneous metastases for palliative radiotherapy or specialized molecularly-targeted protocols, as these sites signify advanced systemic spread and poor prognosis.
  • •Transition to maintenance therapy following first-line chemotherapy in the recurrent setting, which has been shown to improve 3-year overall survival from 37.8% to 52.5% (NNT = 7).

Board Review — High Yield

  • •LACC Trial — Landmark study proving open radical hysterectomy is superior to minimally invasive surgery for cervical cancer survival.
  • •CPS ≥ 1 — The mandatory PD-L1 threshold required to prescribe pembrolizumab in the first-line metastatic setting.
  • •Pelvic Exenteration — The only curative option for central pelvic recurrence after prior definitive radiation.
  • •36 Months — The critical window during which the vast majority of cervical cancer recurrences manifest.
  • •Bevacizumab Toxicity — High risk of bowel perforation and fistulas when used in previously irradiated pelvic fields.
  • •HPV ctDNA — An emerging ultra-sensitive biomarker for detecting molecular relapse before radiographic evidence.
  • •SBRT Dose — 39 Gy in 3 fractions is a standard regimen for treating oligometastatic nodal recurrences.

Deep Dive — Evidence Details

References

  1. [1]

    Abu-Rustum NR, Campos SM, Amarnath S et al.. “Vaginal Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2026). PMID: 41825134 ↗

    L1GUIDELINECited in: Patterns of Recurrence, Prognosis of Recurrent Disease
  2. [2]

    Lorusso D, Colombo N, Dubot C et al.. “Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 39393777 ↗

    L1RCTCited in: Patterns of Recurrence, Prognosis of Recurrent Disease
  3. [3]

    Mayadev J, Vázquez Limón JC, Ramírez Godinez FJ et al.. “Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 40500687 ↗

    L1RCTCited in: Patterns of Recurrence, Prognosis of Recurrent Disease
  4. [4]

    . “Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 19001332 ↗

    L1SR_OBSCited in: Patterns of Recurrence, Prognosis of Recurrent Disease
  5. [5]

    Kitagawa R, Katsumata N, Shibata T et al.. “Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 25732161 ↗

    L1RCTCited in: Patterns of Recurrence, Prognosis of Recurrent Disease
  6. [6]

    Xia L, Zhang K, Tang Y et al.. “Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40561369 ↗

    L1RCTCited in: Patterns of Recurrence
  7. [7]

    Lorusso D, Ferrandina G, Pignata S et al.. “Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group.” Annals of oncology : official journal of the European Society for Medical Oncology (2010). PMID: 19605508 ↗

    L4TRIAL_NONRANDOMCited in: Patterns of Recurrence, Prognosis of Recurrent Disease
  8. [8]

    Thaker PH, Salani R, Brady WE et al.. “A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852).” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 27998970 ↗

    L4TRIAL_NONRANDOMCited in: Patterns of Recurrence, Prognosis of Recurrent Disease
  9. [9]

    Monk BJ, Toita T, Wu X et al.. “Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial.” The Lancet. Oncology (2023). PMID: 38039991 ↗

    L1RCTCited in: Patterns of Recurrence
  10. [10]

    Mileshkin LR, Moore KN, Barnes EH et al.. “Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial.” The Lancet. Oncology (2023). PMID: 37080223 ↗

    L1RCTCited in: Patterns of Recurrence, Prognosis of Recurrent Disease
  11. [11]

    Oaknin A, Moore K, Meyer T et al.. “Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial.” The Lancet. Oncology (2024). PMID: 38608691 ↗

    L4RCTCited in: Patterns of Recurrence, Prognosis of Recurrent Disease
  12. [12]

    Schuurman TN, Schaafsma M, To KH et al.. “Optimising follow-up strategy based on cytology and human papillomavirus after fertility-sparing surgery for early stage cervical cancer: a nationwide, population-based, retrospective cohort study.” The Lancet. Oncology (2023). PMID: 37952541 ↗

    L3COHORTCited in: Patterns of Recurrence
  13. [13]

    Höckel M, Wolf B, Schmidt K et al.. “Surgical resection based on ontogenetic cancer field theory for cervical cancer: mature results from a single-centre, prospective, observational, cohort study.” The Lancet. Oncology (2019). PMID: 31383547 ↗

    L2COHORTCited in: Patterns of Recurrence, Prognosis of Recurrent Disease
  14. [14]

    Symonds RP, Gourley C, Davidson S et al.. “Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial.” The Lancet. Oncology (2015). PMID: 26474517 ↗

    L1RCTCited in: Patterns of Recurrence, Prognosis of Recurrent Disease
  15. [15]

    Vergote I, González-Martín A, Fujiwara K et al.. “Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer.” The New England journal of medicine (2024). PMID: 38959480 ↗

    L1RCTCited in: Patterns of Recurrence, Prognosis of Recurrent Disease
  16. [16]

    Tewari KS, Monk BJ, Vergote I et al.. “Survival with Cemiplimab in Recurrent Cervical Cancer.” The New England journal of medicine (2022). PMID: 35139273 ↗

    L1RCTCited in: Patterns of Recurrence
  17. [17]

    Plante M, Kwon JS, Ferguson S et al.. “Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer.” The New England journal of medicine (2024). PMID: 38416430 ↗

    L1RCTCited in: Patterns of Recurrence, Prognosis of Recurrent Disease
  18. [18]

    Ramirez PT, Frumovitz M, Pareja R et al.. “Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer.” The New England journal of medicine (2018). PMID: 30380365 ↗

    L1RCTCited in: Patterns of Recurrence, Prognosis of Recurrent Disease
  19. [19]

    Tewari KS, Sill MW, Long HJ et al.. “Improved survival with bevacizumab in advanced cervical cancer.” The New England journal of medicine (2014). PMID: 24552320 ↗

    L1RCTCited in: Patterns of Recurrence
  20. [20]

    Vergote I, Van Nieuwenhuysen E, O'Cearbhaill RE et al.. “Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37651655 ↗

    L4TRIAL_NONRANDOMCited in: Patterns of Recurrence
  21. [21]

    Xu Q, Wang J, Sun Y et al.. “Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1-Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35192397 ↗

    L4TRIAL_NONRANDOMCited in: Patterns of Recurrence
  22. [22]

    O'Malley DM, Neffa M, Monk BJ et al.. “Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 34932394 ↗

    L4TRIAL_NONRANDOMCited in: Patterns of Recurrence, Prognosis of Recurrent Disease
  23. [23]

    Naumann RW, Hollebecque A, Meyer T et al.. “Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 31487218 ↗

    L4TRIAL_NONRANDOMCited in: Patterns of Recurrence, Prognosis of Recurrent Disease
  24. [24]

    Lécuru F, Mathevet P, Querleu D et al.. “Bilateral negative sentinel nodes accurately predict absence of lymph node metastasis in early cervical cancer: results of the SENTICOL study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21444878 ↗

    L2TRIAL_NONRANDOMCited in: Patterns of Recurrence
  25. [25]

    Birrer M, Li G, Yunokawa M et al.. “Bintrafusp Alfa for Recurrent or Metastatic Cervical Cancer After Platinum Failure: A Nonrandomized Controlled Trial.” JAMA oncology (2024). PMID: 39052242 ↗

    L4RCTCited in: Patterns of Recurrence
  26. [26]

    Cho WK, Park W, Kim SW et al.. “Postoperative Hypofractionated Intensity-Modulated Radiotherapy With Concurrent Chemotherapy in Cervical Cancer: The POHIM-CCRT Nonrandomized Controlled Trial.” JAMA oncology (2024). PMID: 38662364 ↗

    L2RCTCited in: Patterns of Recurrence
  27. [27]

    Pötter R, Tanderup K, Schmid MP et al.. “MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study.” The Lancet. Oncology (2021). PMID: 33794207 ↗

    L2TRIAL_NONRANDOMCited in: Patterns of Recurrence, Distant Metastatic Disease
  28. [28]

    Coleman RL, Lorusso D, Gennigens C et al.. “Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.” The Lancet. Oncology (2021). PMID: 33845034 ↗

    L4TRIAL_NONRANDOMCited in: Patterns of Recurrence
  29. [29]

    Frumovitz M, Obermair A, Coleman RL et al.. “Quality of life in patients with cervical cancer after open versus minimally invasive radical hysterectomy (LACC): a secondary outcome of a multicentre, randomised, open-label, phase 3, non-inferiority trial.” The Lancet. Oncology (2020). PMID: 32502445 ↗

    L1TRIAL_NONRANDOMCited in: Patterns of Recurrence, Prognosis of Recurrent Disease
  30. [30]

    Penson RT, Huang HQ, Wenzel LB et al.. “Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).” The Lancet. Oncology (2015). PMID: 25638326 ↗

    L1TRIAL_NONRANDOMCited in: Patterns of Recurrence, Prognosis of Recurrent Disease
  31. [31]

    Mayadev JS, Enserro D, Lin YG et al.. “Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer.” JAMA oncology (2020). PMID: 31774464 ↗

    L4TRIAL_NONRANDOMCited in: Patterns of Recurrence
  32. [32]

    Moore DH. “Chemotherapy for advanced, recurrent, and metastatic cervical cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2008). PMID: 18267059 ↗

    L5REVIEW_NARRATIVECited in: Patterns of Recurrence
  33. [33]

    Dyer BA, Zamarin D, Eskandar RN et al.. “Role of Immunotherapy in the Management of Locally Advanced and Recurrent/Metastatic Cervical Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 30659133 ↗

    L5REVIEW_NARRATIVECited in: Patterns of Recurrence, Prognosis of Recurrent Disease
  34. [34]

    Pennington KP, Urban RR, Gray HJ. “Revisiting Minimally Invasive Surgery in the Management of Early-Stage Cervical Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 30659132 ↗

    L5REVIEW_NARRATIVECited in: Patterns of Recurrence, Prognosis of Recurrent Disease
  35. [35]

    Hong DS, Concin N, Vergote I et al.. “Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 31796521 ↗

    L4TRIAL_NONRANDOMCited in: Patterns of Recurrence, Prognosis of Recurrent Disease
  36. [36]

    Oaknin A, Ghamande SA, Kasamatsu Y et al.. “Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 38165683 ↗

    L4TRIAL_NONRANDOMCited in: Patterns of Recurrence
  37. [37]

    Kidd EA, Grigsby PW. “Intratumoral metabolic heterogeneity of cervical cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2008). PMID: 18698042 ↗

    L2TRIAL_NONRANDOMCited in: Patterns of Recurrence
  38. [38]

    Tewari KS. “Immune Checkpoint Blockade in PD-L1-Positive Platinum-Refractory Cervical Carcinoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 31026210 ↗

    L5CASE_REPORTCited in: Patterns of Recurrence
  39. [39]

    Wang X, Zhang Y, Wang C et al.. “Efficacy and safety of first-line therapies for persistent, recurrent, or metastatic cervical cancer: a systematic review and exploratory network meta-analysis of immunotherapy.” Frontiers in immunology (2026). PMID: 42079658 ↗

    L1SR_OBSCited in: Patterns of Recurrence, Prognosis of Recurrent Disease
  40. [40]

    Park JY, Kim DY, Kim JH et al.. “Management of occult invasive cervical cancer found after simple hysterectomy.” Annals of oncology : official journal of the European Society for Medical Oncology (2010). PMID: 19858083 ↗

    L3OTHERCited in: Patterns of Recurrence, Prognosis of Recurrent Disease
  41. [41]

    Cho Y, Kim KH, Yoon HI et al.. “Tumor-related leukocytosis is associated with poor radiation response and clinical outcome in uterine cervical cancer patients.” Annals of oncology : official journal of the European Society for Medical Oncology (2016). PMID: 27502717 ↗

    L3OTHERCited in: Patterns of Recurrence, Prognosis of Recurrent Disease
  42. [42]

    Li Z, Yu CP, Zhong Y et al.. “Sam68 expression and cytoplasmic localization is correlated with lymph node metastasis as well as prognosis in patients with early-stage cervical cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 21700735 ↗

    L3OTHERCited in: Patterns of Recurrence
  43. [43]

    Nakamura K, Abarzua F, Hongo A et al.. “Hepatocyte growth factor activator inhibitor-2 (HAI-2) is a favorable prognosis marker and inhibits cell growth through the apoptotic pathway in cervical cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2009). PMID: 18689863 ↗

    L3OTHERCited in: Patterns of Recurrence
  44. [44]

    Kodama J, Hasengaowa, Kusumoto T et al.. “Association of CXCR4 and CCR7 chemokine receptor expression and lymph node metastasis in human cervical cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 17032700 ↗

    L3OTHERCited in: Patterns of Recurrence
  45. [45]

    Ma J, Wang G, Wang W et al.. “Extended-field intensity-modulated radiation therapy and high-dose-rate brachytherapy with concurrent chemotherapy for cervical cancer with positive para-aortic or common iliac lymph nodes: a multicenter prospective cohort study.” Journal of gynecologic oncology (2026). PMID: 42210768 ↗

    L2COHORTCited in: Patterns of Recurrence
  46. [46]

    Wei Y, Song F, Wang W. “Expression levels of serum SCC, HE4, and TSGF in cervical cancer patients and their correlation with recurrence: a retrospective study.” Frontiers in medicine (2026). PMID: 42200085 ↗

    L3COHORTCited in: Patterns of Recurrence
  47. [47]

    Zhang L, Yang J, Zhang P et al.. “Association between log odds of positive lymph nodes and survival in surgically treated cervical cancer patients: a SEER database-based cohort study.” World journal of surgical oncology (2026). PMID: 41998619 ↗

    L3COHORTCited in: Patterns of Recurrence
  48. [48]

    Han K, Zou J, Zhao Z et al.. “Clinical Validation of Human Papilloma Virus Circulating Tumor DNA for Early Detection of Residual Disease After Chemoradiation in Cervical Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 37972346 ↗

    L2OTHERCited in: Patterns of Recurrence
  49. [49]

    Ogasawara A, Suzuki S, Oda K et al.. “Phase II study of pembrolizumab plus olaparib in recurrent cervical cancer progressing after platinum-based chemotherapy (GOTIC-025).” Gynecologic oncology (2026). PMID: 42013608 ↗

    L4TRIAL_NONRANDOMCited in: Patterns of Recurrence
  50. [50]

    Van Nieuwenhuysen E, Vergote I, Randall LM et al.. “Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study.” Gynecologic oncology (2026). PMID: 42000372 ↗

    L4TRIAL_NONRANDOMCited in: Patterns of Recurrence
  51. [51]

    Yang Y, Yu M, Zeng M. “Distant metastasis in patients with cervical cancer: A systematic review and meta-analysis of incidence rates and common sites.” International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics (2026). PMID: 42171512 ↗

    L2SR_OBSCited in: Patterns of Recurrence
  52. [52]

    Saini SK, Srivastava S, Goel A et al.. “Outcomes of Stage IVA Cervical Cancer Treated with Radiation Therapy: A Systematic Review and Meta-Analysis.” International journal of radiation oncology, biology, physics (2026). PMID: 42034194 ↗

    L2SR_OBSCited in: Patterns of Recurrence
  53. [53]

    Wenzel HHB, Olthof EP, Bekkers RLM et al.. “Primary or adjuvant chemoradiotherapy for cervical cancer with intraoperative lymph node metastasis - A review.” Cancer treatment reviews (2022). PMID: 34773774 ↗

    L5REVIEW_NARRATIVECited in: Patterns of Recurrence, Distant Metastatic Disease
  54. [54]

    Pectasides D, Kamposioras K, Papaxoinis G et al.. “Chemotherapy for recurrent cervical cancer.” Cancer treatment reviews (2008). PMID: 18657909 ↗

    L5REVIEW_NARRATIVECited in: Patterns of Recurrence, Prognosis of Recurrent Disease
  55. [55]

    Monk BJ, Enomoto T, Kast WM et al.. “Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials.” Cancer treatment reviews (2022). PMID: 35413489 ↗

    L5REVIEW_NARRATIVECited in: Patterns of Recurrence
  56. [56]

    Tolcher A, Hamilton E, Coleman RL. “The evolving landscape of antibody-drug conjugates in gynecologic cancers.” Cancer treatment reviews (2023). PMID: 37023499 ↗

    L5REVIEW_NARRATIVECited in: Patterns of Recurrence
  57. [57]

    Gennigens C, Jerusalem G, Lapaille L et al.. “Recurrent or primary metastatic cervical cancer: current and future treatments.” ESMO open (2022). PMID: 36108558 ↗

    L5REVIEW_NARRATIVECited in: Patterns of Recurrence
  58. [58]

    Cabel L, Bonneau C, Bernard-Tessier A et al.. “HPV ctDNA detection of high-risk HPV types during chemoradiotherapy for locally advanced cervical cancer.” ESMO open (2021). PMID: 34022731 ↗

    L2OTHERCited in: Patterns of Recurrence
  59. [59]

    Tu H, Huang H, Li Y et al.. “Sentinel-Lymph-Node Biopsy Alone or with Lymphadenectomy in Cervical Cancer.” The New England journal of medicine (2025). PMID: 41092328 ↗

    L1OTHERCited in: Patterns of Recurrence, Prognosis of Recurrent Disease
  60. [60]

    Melamed A, Margul DJ, Chen L et al.. “Survival after Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer.” The New England journal of medicine (2018). PMID: 30379613 ↗

    L3OTHERCited in: Patterns of Recurrence, Prognosis of Recurrent Disease
  61. [61]

    Brunson A, Wun T, Abrahão R et al.. “Metastatic Recurrence Among Adolescents and Young Adults With Cancer.” JAMA oncology (2026). PMID: 41296369 ↗

    L3OTHERCited in: Patterns of Recurrence
  62. [62]

    Lheureux S, Butler MO, Clarke B et al.. “Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma.” JAMA oncology (2018). PMID: 29145543 ↗

    L2OTHERCited in: Patterns of Recurrence
  63. [63]

    Jiang Q, Zhang Z, Zhou J et al.. “The role of p53-mediated signaling pathways in nicotine-induced cancer: a systematic review.” Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association (2026). PMID: 42250592 ↗

    L5SR_OBSCited in: Patterns of Recurrence
  64. [64]

    Liu Y, Hu Y, Wang H et al.. “Clinicopathological and Prognostic Characteristics of Gastric-Type Endocervical Adenocarcinoma: A Nested Case-Control Study.” Cancers (2026). PMID: 41976390 ↗

    L3CASE_CONTROLCited in: Patterns of Recurrence
  65. [65]

    Miller KM, Friedman CF. “Bifunctional Blockade: A Novel Immunotherapy Approach for Cervical Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2022). PMID: 35947045 ↗

    L5OTHERCited in: Patterns of Recurrence
  66. [66]

    Tewari KS, Monk BJ. “New strategies in advanced cervical cancer: from angiogenesis blockade to immunotherapy.” Clinical cancer research : an official journal of the American Association for Cancer Research (2014). PMID: 25104084 ↗

    L5REVIEW_NARRATIVECited in: Patterns of Recurrence
  67. [67]

    Seo A, Xiao W, Gjyshi O et al.. “Human Papilloma Virus Circulating Cell-Free DNA Kinetics in Patients with Cervical Cancer Undergoing Definitive Chemoradiation.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 39680029 ↗

    L2OTHERCited in: Patterns of Recurrence
  68. [68]

    Sasano T, Mabuchi S, Kozasa K et al.. “The Highly Metastatic Nature of Uterine Cervical/Endometrial Cancer Displaying Tumor-Related Leukocytosis: Clinical and Preclinical Investigations.” Clinical cancer research : an official journal of the American Association for Cancer Research (2018). PMID: 29752277 ↗

    L3OTHERCited in: Patterns of Recurrence
  69. [69]

    Sivars L, Jylhä C, Crona Guterstam Y et al.. “Cell-Free Human Papillomavirus DNA Is a Sensitive Biomarker for Prognosis and for Early Detection of Relapse in Locally Advanced Cervical Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 38669077 ↗

    L2OTHERCited in: Patterns of Recurrence, Prognosis of Recurrent Disease
  70. [70]

    Lee MY, Chou CY, Tang MJ et al.. “Epithelial-mesenchymal transition in cervical cancer: correlation with tumor progression, epidermal growth factor receptor overexpression, and snail up-regulation.” Clinical cancer research : an official journal of the American Association for Cancer Research (2008). PMID: 18676743 ↗

    L4OTHERCited in: Patterns of Recurrence
  71. [71]

    Da Silva DM, Enserro DM, Mayadev JS et al.. “Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929).” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 32816895 ↗

    L2OTHERCited in: Patterns of Recurrence, Distant Metastatic Disease, Prognosis of Recurrent Disease
  72. [72]

    Thompson LMA, Loecher N, Albizu-Jacob A et al.. “Post-traumatic reactions and quality of life after pelvic exenteration for gynecologic cancer: a retrospective cohort study.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2024). PMID: 39404886 ↗

    L4COHORTCited in: Local-Regional Recurrence
  73. [73]

    Mittal P, Chopra S, Charnalia M et al.. “Patterns of Relapse After Adjuvant Chemoradiation for Cervical Cancer in a Phase 3 Clinical Trial (PARCER): An Evaluation of Updated NRG Oncology/RTOG Target Delineation Guidelines.” International journal of radiation oncology, biology, physics (2022). PMID: 35157993 ↗

    L1RCTCited in: Local-Regional Recurrence
  74. [74]

    Seebacher V, Rockall A, Nobbenhuis M et al.. “The impact of nutritional risk factors and sarcopenia on survival in patients treated with pelvic exenteration for recurrent gynaecological malignancy: a retrospective cohort study.” Archives of gynecology and obstetrics (2022). PMID: 34734326 ↗

    L3COHORTCited in: Local-Regional Recurrence
  75. [75]

    Okuma K, Murakami N, Inaba K et al.. “Gel spacer-assisted salvage brachytherapy for pelvic recurrence after definitive chemoradiotherapy in cervical cancer: A single-institution retrospective study.” Brachytherapy (2025). PMID: 40769797 ↗

    L4COHORTCited in: Local-Regional Recurrence
  76. [76]

    Yu JH, Tong CJ, Huang QD et al.. “Long-term outcomes of pelvic exenterations for gynecological malignancies: a single-center retrospective cohort study.” BMC cancer (2024). PMID: 38229045 ↗

    L3COHORTCited in: Local-Regional Recurrence
  77. [77]

    Sadozye AH. “Re-irradiation in Gynaecological Malignancies: A Review.” Clinical oncology (Royal College of Radiologists (Great Britain)) (2018). PMID: 29233573 ↗

    L4SR_OBSCited in: Local-Regional Recurrence
  78. [78]

    Conte C, Della Corte L, Pelligra S et al.. “Assessment of Salvage Surgery in Persistent Cervical Cancer after Definitive Radiochemotherapy: A Systematic Review.” Medicina (Kaunas, Lithuania) (2023). PMID: 36837394 ↗

    L2SR_OBSCited in: Local-Regional Recurrence
  79. [79]

    Bacalbasa N, Balescu I, Vilcu M et al.. “Pelvic Exenteration for Locally Advanced and Relapsed Pelvic Malignancies - An Analysis of 100 Cases.” In vivo (Athens, Greece) (2019). PMID: 31662557 ↗

    L4SR_OBSCited in: Local-Regional Recurrence
  80. [80]

    Hwang IS, Hur SY. “Entero-vascular fistula following radiotherapy in a patient with recurrent cervical cancer post-pelvic exenteration: a case report.” BMC women's health (2025). PMID: 40634912 ↗

    L4CASE_REPORTCited in: Local-Regional Recurrence
  81. [81]

    Ohno R, Matsumoto Y, Nagano H et al.. “Combined laparoscopic and transperineal endoscopic total pelvic exenteration for the vaginal stump recurrence of cervical cancer.” Journal of gynecologic oncology (2022). PMID: 34910397 ↗

    L4CASE_REPORTCited in: Local-Regional Recurrence
  82. [82]

    Kanao H, Aoki Y, Fusegi A et al.. “Should indications for laterally extended endopelvic resection (LEER) exclude patients with sciatica?” Journal of gynecologic oncology (2020). PMID: 32808494 ↗

    L4CASE_REPORTCited in: Local-Regional Recurrence
  83. [83]

    Konstantinidis IT, Chu W, Tozzi F et al.. “Robotic Total Pelvic Exenteration: Video-Illustrated Technique.” Annals of surgical oncology (2017). PMID: 28808931 ↗

    L4CASE_REPORTCited in: Local-Regional Recurrence
  84. [84]

    Niazmand A, Nedaeinia R, Vatandoost N et al.. “The impacts of dipeptidyl- peptidase 4 (DPP-4) inhibitors on common female malignancies: A systematic review.” Gene (2024). PMID: 38866262 ↗

    L2SR_OBSCited in: Distant Metastatic Disease
  85. [85]

    Wang X, Wu Y, Huang J et al.. “Bispecific antibodies (PD-1/CTLA-4) vs. PD-1 inhibitors with platinum-based chemotherapy±bevacizumab as first-line therapy for persistent, recurrent, or metastatic cervical cancer: a retrospective matched cohort study.” Cancer immunology, immunotherapy : CII (2025). PMID: 41136631 ↗

    L3COHORTCited in: Distant Metastatic Disease
  86. [86]

    Lang J, Liu Q, Ji R et al.. “Complete remission of a high-risk, locally advanced cervical cancer with para-aortic lymph node metastases treated with first-line tislelizumab plus bevacizumab combined with chemotherapy followed by radiotherapy with maintenance therapy: a case report.” Frontiers in immunology (2025). PMID: 40375998 ↗

    L4CASE_REPORTCited in: Distant Metastatic Disease
  87. [87]

    Guo L, Liu Y, Zhang S et al.. “Case report: Cutaneous metastasis of squamous cervical carcinoma: complete regression after molecular diagnosis.” Frontiers in immunology (2024). PMID: 39902051 ↗

    L4CASE_REPORTCited in: Distant Metastatic Disease
  88. [88]

    Ni J, Dong X, Shou H et al.. “Second-line monotherapy with a PD-1/CTLA-4 inhibitor effectively treated multiple brain and lung metastases of cervical cancer: a case report.” Frontiers in immunology (2024). PMID: 39469707 ↗

    L4CASE_REPORTCited in: Distant Metastatic Disease
  89. [89]

    Zeng Q, Huang S, Jiang T. “The Multiple Roles and Targeting Strategies of LonP1 in the Occurrence and Development of Cancer.” BioFactors (Oxford, England) (2026). PMID: 42219609 ↗

    L5REVIEW_NARRATIVECited in: Distant Metastatic Disease
  90. [90]

    Xu Z, Zhang L, Wang H et al.. “Combined neutrophil-to-lymphocyte ratio and nomogram for predicting progression-free survival in recurrent/metastatic cervical cancer treated with immune checkpoint inhibitors.” Frontiers in immunology (2026). PMID: 42058197 ↗

    L3OTHERCited in: Distant Metastatic Disease
  91. [91]

    Liu R, Lin Z, Li Y et al.. “Mechanistic insights into the roles of astragalosides and Astragalus polysaccharides in gynecological and breast cancers (Review).” Oncology reports (2026). PMID: 41860034 ↗

    L5REVIEW_NARRATIVECited in: Distant Metastatic Disease
  92. [92]

    Liu J, Zhou L, Yao P et al.. “M5C-driven stabilization of SERPINB5 promotes cervical cancer progression and chemotherapy resistance.” Cell death & disease (2026). PMID: 41673397 ↗

    L5OTHERCited in: Distant Metastatic Disease
  93. [93]

    Yu H, Chen J, Lin J et al.. “Cadonilimab rechallenge in patients with recurrent or metastatic cervical cancer following prior PD-1/PD-L1 inhibitor failure: a retrospective multicenter study.” Frontiers in immunology (2025). PMID: 41583427 ↗

    L4OTHERCited in: Distant Metastatic Disease
  94. [94]

    Wang M, Fan J, Mu B et al.. “HDAC5 stabilization by tubeimoside I suppresses cervical cancer metastasis via inhibiting H3K27ac/KPNA2 axis.” British journal of cancer (2026). PMID: 41507559 ↗

    L5OTHERCited in: Distant Metastatic Disease
  95. [95]

    Liu Z, Zhang S, Wang Y et al.. “Development and validation of immunotherapy nomogram for predicting the efficacy and prognosis of recurrent and metastatic cervical cancer.” Frontiers in immunology (2025). PMID: 41438759 ↗

    L3OTHERCited in: Distant Metastatic Disease
  96. [96]

    Chen L, Chen W, Lin Y et al.. “Serum immune parameters as predictors for treatment outcomes in cervical cancer treated with concurrent chemo-radiotherapy.” Chinese medical journal (2025). PMID: 41199468 ↗

    L3OTHERCited in: Distant Metastatic Disease
  97. [97]

    Mathibela SP, Ncube KN, Lebelo MT et al.. “Advancing cervical cancer treatment: integrating cannabinoids, combination therapies and nanotechnology.” Journal of cancer research and clinical oncology (2025). PMID: 41102423 ↗

    L5REVIEW_NARRATIVECited in: Distant Metastatic Disease
  98. [98]

    Lahouti S, Doustvandi MA, Yari A et al.. “Photodynamic therapy boosts the anti-proliferative activity of oxaliplatin in cervical cancer cells by regulating stemness-related genes.” Medical oncology (Northwood, London, England) (2025). PMID: 41081980 ↗

    L5OTHERCited in: Distant Metastatic Disease
  99. [99]

    Ma Y, Lin S, Chen Q et al.. “Updated efficacy and predictive biomarkers of QL1706, a bifunctional PD-1/CTLA-4 dual blocker in advanced solid tumors-A phase 1/1b study.” Cell reports. Medicine (2025). PMID: 41045933 ↗

    L2TRIAL_NONRANDOMCited in: Distant Metastatic Disease
  100. [100]

    Jenei V, Muszka Z, Stigelmayer Á et al.. “Anthracycline Treatments and the Presence of Tumor Cells Synergistically Modify the Composition of Macrophage Subpopulations in the Co-Culture System.” International journal of molecular sciences (2025). PMID: 41009763 ↗

    L5OTHERCited in: Distant Metastatic Disease
  101. [101]

    de Sousa C, Eksteen C, Engelbrecht AM. “Resveratrol: Sensitising CD44+ Cervical Cancer Cells to Carboplatin and Mitigating Metastasis.” Cancer medicine (2025). PMID: 40888184 ↗

    L5REVIEW_NARRATIVECited in: Distant Metastatic Disease
  102. [102]

    Ito K, Nakajima Y, Ogawa H et al.. “Phase I/II study of stereotactic body radiotherapy boost in patients with cervical cancer ineligible for intracavitary brachytherapy.” Japanese journal of radiology (2024). PMID: 38625476 ↗

    L2TRIAL_NONRANDOMCited in: Oligometastatic Disease
  103. [103]

    Cengiz M, Dogan A, Ozyigit G et al.. “Comparison of intracavitary brachytherapy and stereotactic body radiotherapy dose distribution for cervical cancer.” Brachytherapy (2012). PMID: 22192496 ↗

    L4TRIAL_NONRANDOMCited in: Oligometastatic Disease
  104. [104]

    Park HJ, Chang AR, Seo Y et al.. “Stereotactic Body Radiotherapy for Recurrent or Oligometastatic Uterine Cervix Cancer: A Cooperative Study of the Korean Radiation Oncology Group (KROG 14-11).” Anticancer research (2015). PMID: 26254414 ↗

    L3TRIAL_NONRANDOMCited in: Oligometastatic Disease
  105. [105]

    Ito K, Kito S, Nakajima Y et al.. “Determining the recommended dose of stereotactic body radiotherapy boost in patients with cervical cancer who are unsuitable for intracavitary brachytherapy: a phase I dose-escalation study.” Japanese journal of clinical oncology (2019). PMID: 31112278 ↗

    L2TRIAL_NONRANDOMCited in: Oligometastatic Disease
  106. [106]

    Peng C, Li X, Tang W et al.. “Real-world outcomes of first-line maintenance therapy for recurrent or metastatic cervical cancer: A multi-center retrospective study.” International immunopharmacology (2024). PMID: 38330795 ↗

    L3COHORTCited in: Oligometastatic Disease
  107. [107]

    da Silva JL, de Miranda AVSS, Arruda GV et al.. “Stereotactic body radiotherapy as an alternative to brachytherapy in cervical cancer (SCORE): A systematic review and meta-analysis.” Critical reviews in oncology/hematology (2025). PMID: 40460923 ↗

    L1SR_OBSCited in: Oligometastatic Disease
  108. [108]

    Mendez LC, Leung E, Cheung P et al.. “The Role of Stereotactic Ablative Body Radiotherapy in Gynaecological Cancers: A Systematic Review.” Clinical oncology (Royal College of Radiologists (Great Britain)) (2017). PMID: 28209456 ↗

    L2SR_OBSCited in: Oligometastatic Disease
  109. [109]

    Chargari C, Renard S, Espenel S et al.. “[Can stereotactic body radiotherapy replace brachytherapy for locally advanced cervical cancer? French society for radiation oncology statement].” Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique (2020). PMID: 32753238 ↗

    L5GUIDELINECited in: Oligometastatic Disease
  110. [110]

    Shenker R, Stephens SJ, Davidson B et al.. “Role of stereotactic body radiotherapy in gynecologic radiation oncology.” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2022). PMID: 35256426 ↗

    L5REVIEW_NARRATIVECited in: Oligometastatic Disease
  111. [111]

    Miranda AVSS, da Silva JL, Andrade DAP et al.. “Stereotactic body radiotherapy boost as an alternative to brachytherapy for cervical cancer: A scoping review.” Critical reviews in oncology/hematology (2024). PMID: 39299408 ↗

    L5REVIEW_NARRATIVECited in: Oligometastatic Disease
  112. [112]

    Youn JW, Hur SY, Woo JW et al.. “Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial.” The Lancet. Oncology (2020). PMID: 33271094 ↗

    L2TRIAL_NONRANDOMCited in: Prognosis of Recurrent Disease
  113. [113]

    Höckel M, Trott S, Dornhöfer N et al.. “Vulvar field resection based on ontogenetic cancer field theory for surgical treatment of vulvar carcinoma: a single-centre, single-group, prospective trial.” The Lancet. Oncology (2018). PMID: 29530664 ↗

    L2TRIAL_NONRANDOMCited in: Prognosis of Recurrent Disease
  114. [114]

    Höckel M, Horn LC, Manthey N et al.. “Resection of the embryologically defined uterovaginal (Müllerian) compartment and pelvic control in patients with cervical cancer: a prospective analysis.” The Lancet. Oncology (2009). PMID: 19482513 ↗

    L2TRIAL_NONRANDOMCited in: Prognosis of Recurrent Disease
  115. [115]

    Zhou L, Sun C, Diao P et al.. “Efficacy and safety of adding immune checkpoint inhibitors to standard chemotherapy or chemoradiotherapy for advanced or recurrent cervical cancer: a meta-analysis.” Frontiers in immunology (2026). PMID: 41869324 ↗

    L1SR_OBSCited in: Prognosis of Recurrent Disease
  116. [116]

    Zhou J, Ye W, Ranarisoa SN et al.. “Comparison of drug regimens for recurrent or metastatic cervical cancer: a systematic review and network meta-analysis.” Frontiers in immunology (2026). PMID: 41822503 ↗

    L1SR_OBSCited in: Prognosis of Recurrent Disease
  117. [117]

    Vincze Á, Márai D, Frivaldszky L et al.. “Neoadjuvant chemotherapy enables fertility preservation without compromising oncologic outcomes in early cervical cancer ≥2 cm: A systematic review and meta-analysis.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 41687593 ↗

    L1SR_OBSCited in: Prognosis of Recurrent Disease
  118. [118]

    Zhuang Q, Liu Y. “Efficacy and safety of Cadonilimab in the treatment of recurrent/metastatic and advanced cervical cancer: a systematic review and meta-analysis.” Frontiers in immunology (2025). PMID: 41601625 ↗

    L2SR_OBSCited in: Prognosis of Recurrent Disease
  119. [119]

    Saad A, Taylor A, Felder S et al.. “De-escalating first-line treatment in stage IVB or recurrent cervical cancer: outcomes of immunotherapy alone and systemic review.” The oncologist (2025). PMID: 40421960 ↗

    L4SR_OBSCited in: Prognosis of Recurrent Disease
  120. [120]

    Bale CA, Pearce JV, Deng X et al.. “Prognostic value of FDG-PET SUV changes in cervical cancer following radiation therapy: a retrospective cohort study.” Archives of gynecology and obstetrics (2026). PMID: 41609820 ↗

    L3COHORTCited in: Prognosis of Recurrent Disease
  121. [121]

    Kim SI, Kim JW, Kwon JS et al.. “Comparative outcomes of simple versus radical hysterectomy in patients with and without very low-risk early-stage cervical cancer: An exploratory analysis from the Gynecologic Cancer Intergroup/Canadian Cancer Trials Group CX.5/SHAPE trial.” Gynecologic oncology (2026). PMID: 41520567 ↗

    L1RCTCited in: Prognosis of Recurrent Disease
  122. [122]

    Kitami K, Kuji S, Kamiya N et al.. “Real-world safety and efficacy of immune checkpoint inhibitors in Japanese patients with persistent, recurrent, or metastatic cervical cancer: a multicenter prospective and retrospective study.” International journal of clinical oncology (2026). PMID: 41504989 ↗

    L3COHORTCited in: Prognosis of Recurrent Disease
  123. [123]

    Uppal S, Gehrig PA, Peng K et al.. “Recurrence Rates in Patients With Cervical Cancer Treated With Abdominal Versus Minimally Invasive Radical Hysterectomy: A Multi-Institutional Retrospective Review Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 32031867 ↗

    L3REVIEW_NARRATIVECited in: Prognosis of Recurrent Disease
  124. [124]

    Rose PG, Java J, Whitney CW et al.. “Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 25732170 ↗

    L2OTHERCited in: Prognosis of Recurrent Disease
  125. [125]

    Höckel M, Hentschel B, Horn LC. “Association between developmental steps in the organogenesis of the uterine cervix and locoregional progression of cervical cancer: a prospective clinicopathological analysis.” The Lancet. Oncology (2014). PMID: 24656439 ↗

    L2OTHERCited in: Prognosis of Recurrent Disease
  126. [126]

    Baudin L, Zanella L, Lebeau A et al.. “Nonmetastatic Para-aortic Lymph Node Remodeling as a Predictor of Outcome in Locally Advanced Cervical Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 41779008 ↗

    L3OTHERCited in: Prognosis of Recurrent Disease

Revision History

All updates applied to this page

Loading revisions…